Current status and future prospects of nanocarrier-mediated miRNA delivery for osteoarthritis therapy

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Osteoarthritis (OA) is a common degenerative joint disease whose pathogenesis involves multiple pathways, including inflammatory responses, cartilage matrix metabolism, cell proliferation, and apoptosis. Currently, effective clinical treatments are lacking. MicroRNAs (miRNAs) are associated with the pathogenesis of OA and represent potential therapeutic agents for this disease. However, issues such as miRNA instability, off-target effects, and low cellular uptake efficiency have limited their clinical application. Nanocarriers, which are widely used for targeted drug delivery, offer a convenient approach for miRNA-based OA therapy. Numerous studies have employed nanomaterials such as polymer-based, lipid-based, inorganic nanoparticles, and extracellular vesicles (EVs) to deliver miRNAs, effectively inhibiting the progression of OA and achieving therapeutic goals. This review summarizes research advances in the use of nanoparticles to deliver miRNAs for the treatment of OA, explores the associated clinical prospects and challenges, and proposes potential pathways toward intelligent, precise, and personalized therapy, with the aim of informing miRNA-mediated gene therapy for OA.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.